Clinical Trial Update: Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance [Phase 2]

View source ↗

Summary

A Phase 2 study of the CCR2 antagonist BMS-741672 for insulin resistance in type 2 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• BMS-741672

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Type 2 Diabetes | Phase 2 | Status: COMPLETED